Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas

Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase (FT). FT catalyzes the post-translational attachment of farnesyl groups to signaling proteins that are required for localization to cell membranes. Although all RAS isoforms are FT substrates, only HRAS is exclusively depen...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Gilardi, Mara, Wang, Zhiyong, Proietto, Marco, Chillà, Anastasia, Calleja-Valera, Juan Luis, Goto, Yusuke, Vanoni, Marco, Janes, Matthew R., Mikulski, Zbigniew, Gualberto, Antonio, Molinolo, Alfredo A., Ferrara, Napoleone, Gutkind, J. Silvio, Burrows, Francis
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484242/
https://ncbi.nlm.nih.gov/pubmed/32727882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-0958
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi